Popular Articles

L.A. Times, NYT Opinion Pieces Discuss International Women's Health Issues
The Los Angeles Times and the New York Times recently published opinion pieces examining issues related to international women"s health. Summaries appear below.~ Michelle Goldberg, Los Angeles Times: The solution to addressing issues of over-population and under-population in various parts of the world is "giving women more control over their fertility and their lives," Goldberg, author of "The Means of Reproduction: Sex, Power and the Future of the World," writes in a Times opinion piece. Goldberg says that both problems are "symptoms of countries" failures to meet women"s needs." Citing United Nations data, Goldberg writes that the world"s population is growing at an "unsustainable" rate of 78 million people annually, and it will probably continue to increase by 70 million or 75 million annually through 2020. Almost all of that growth will occur in developing countries, she says. "The ethical and effective way to counter rapid population growth is to bolster women"s rights and improve their access to family planning," as well as access to education, Goldberg writes, adding that "study after study has found that girls who go to school marry later and have fewer, healthier children." Meanwhile, some developed countries -- including Japan, Russia, Italy and Spain -- are seeing a decline in birth rates, a fact that some social conservatives are using "to argue for restrictions on women"s rights." According to Goldberg, "Fertility is reaching dangerously low levels in countries where social attitudes and institutions haven"t caught up with women"s desire to combine work and family. When faced with men who are unwilling to share domestic burdens, inflexible workplaces and day-care shortages, many women respond by having fewer children." However, "when societies make it possible for women to combine having children with pursuing their other ambitions, fertility rates are fine," Goldberg says. She adds, "Give women freedom and support, and they will find reproductive equilibrium, so that when societies do shrink or grow, they do so in a manageable way" (Goldberg, Los Angeles Times, 5/17).~ Nicholas Kristof, New York Times: About 500,000 women "die annually from complications related to pregnancy or childbirth without attracting much interest because the victims are typically among the most voiceless people in the world: impoverished, rural, uneducated and female," Kristof writes in a Times opinion piece. He adds, "It"s no mystery how to save the lives of pregnant women; what"s lacking is the will and res." Kristof writes that Sierra Leone, which has the highest maternal mortality rate in the world, "is now making progress with the help of the United Nations Population Fund." Former President George W. Bush cut off U.S. funding for UNFPA, but President Obama has restored the funding. Kristof adds that a bill (H.R. 1410) that would "establish American leadership in this area ... has attracted pathetically little attention." He continues that if the lives of women in West Africa "were a priority, there would be many simple ways to keep them alive," such as providing them with bed nets to help protect against malaria or iron tablets to fight anemia at a cost of "just a few dollars" (Kristof, New York Times, 5/17).
generic viagra online
Genetic Factors Play Lead Role For Adolescent Crime Victims
Genes trump environment as the primary reason that some adolescents are more likely than others to be victimized by crime, according to groundbreaking research led by distinguished criminologist Kevin M. Beaver of The Florida State University.
News of the day
News From The June Issue Of CHEST
PULMONARY HYPERTENSION: A CASE OF MISTAKEN IDENTITY?
Public Health

EyeGate Pharma Announces That EGP-437 Improved Signs And Symptoms Of Dry Eye Syndrome In A Phase II Study

Based on the top-level analysis of a Phase II study, EyeGate Pharma announces that EGP-437, a corticosteroid solution administered by a non-invasive ocular drug delivery system, improved signs and symptoms in patients with dry eye syndrome (DES). For the dry eye clinical trial, EyeGate worked with Ora, Inc., a leading global clinical research and development organization located in Andover, MA. Over the past 30 years, Ora has been a pioneering force in the development of advanced research models across the field of ophthalmology. This Phase II single-center, randomized (105 patients), double-masked, placebo-controlled patient study evaluated the safety and efficacy of a corticosteroid solution (EGP-437) administered by the EyeGate® II Delivery System (at two dose levels) twice over a three-week period. Ora"s Controlled Adverse Environment (CAE) clinical research system, which simulates the acute environmental challenges regularly faced by DES patients, was used for this study. In the top-level analysis, investigators observed that EGP-437 significantly (p About Dry Eye Syndrome Dry Eye Syndrome (DES) is the most prevalent form of ocular discomfort and irritation, accounting for one in four patient visits to a general ophthalmologist. It is estimated that as many as 20 to 40 million Americans suffer from DES, including a significant number of patients who suffer from DES after Lasik surgery. Symptoms such as pain, light sensitivity, blurred vision, and irritation decrease the quality of life for patients and can ultimately lead to loss of function and blindness. The incidence of DES is increasing due to environmental factors, the aging population and the increasing prevalence of co-morbid diseases such as diabetes. There is no cure for DES, and the few treatment options currently available primarily provide temporary symptomatic relief. About Ora, Inc. Ora is the world"s leading independent ophthalmic drug and device development firm. Ora provides technology-based concept-to-market services and solutions that accelerate development timelines and improve the scientific quality of clinical research. Over the past 30 years, Ora has played a central role in the development and FDA approval of more than 30 ophthalmic products. For more information, please visit http://www.oraclinical.com. EyeGate Pharma


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):